STOCK TITAN
  1. Home
  2. Sec-filings
  3. AVTX
  4. [EFFECT] Avalo Therapeutics, Inc. SEC Filing

[EFFECT] Avalo Therapeutics, Inc. SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
EFFECT

Rhea-AI Filing Summary

Analyzing...
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: January 20, 2026 9:00 A.M.
Form: S-3
CIK: 0001534120
Company Name: Avalo Therapeutics, Inc.
File Number: 333-292614

Source: View Original Filing on SEC EDGAR

Stock AVTX logo
Avalo Therapeutics Inc

NASDAQ:AVTX

AVTX Rankings

#4060 Ranked by Market Cap
N/A Ranked by Dividends

AVTX Latest News

Nov 17, 2025
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Nov 6, 2025
Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates
Nov 3, 2025
Avalo Therapeutics to Participate in Upcoming Investor Conferences
Oct 29, 2025
Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa
Oct 1, 2025
Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources

AVTX Latest SEC Filings

Jan 8, 2026
[S-3] Avalo Therapeutics, Inc. Shelf Registration Statement
Jan 12, 2026
[8-K] Avalo Therapeutics, Inc. Reports Material Event
Dec 12, 2025
[Form 4] Avalo Therapeutics, Inc. Insider Trading Activity
Dec 12, 2025
[Form 4] Avalo Therapeutics, Inc. Insider Trading Activity
Dec 12, 2025
[Form 4] Avalo Therapeutics, Inc. Insider Trading Activity

AVTX Stock Data

300.83M
15.91M
5.26%
64.11%
0.42%
Biotechnology
Pharmaceutical Preparations
Link
United States
WAYNE